➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: January 26, 2021

DrugPatentWatch Database Preview


➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Temozolomide, and what generic alternatives are available?

Temozolomide is a drug marketed by Accord Hlthcare, Amneal Pharms, Ani Pharms Inc, Apotex Inc, Barr, Chartwell, Chemi Spa, Deva Holding As, Lannett Co Inc, Mylan, Rising, Sun Pharm, Watson Labs Teva, and Zydus Pharms. and is included in fourteen NDAs.

The generic ingredient in TEMOZOLOMIDE is temozolomide. There are sixteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the temozolomide profile page.

US ANDA Litigation and Generic Entry Outlook for Temozolomide

A generic version of TEMOZOLOMIDE was approved as temozolomide by BARR on March 1st, 2010.

  Start Trial

Drug patent expirations by year for TEMOZOLOMIDE
Drug Prices for TEMOZOLOMIDE

See drug prices for TEMOZOLOMIDE

Recent Clinical Trials for TEMOZOLOMIDE

Identify potential brand extensions & 505(b)(2) entrants

Hangzhou Normal UniversityPhase 2
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2
ClinSearchPhase 1

See all TEMOZOLOMIDE clinical trials

Pharmacology for TEMOZOLOMIDE
Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Paragraph IV (Patent) Challenges for TEMOZOLOMIDE
Tradename Dosage Ingredient NDA Submissiondate
TEMODAR CAPSULE;ORAL temozolomide 021029 2008-03-24
TEMODAR CAPSULE;ORAL temozolomide 021029 2007-03-20

US Patents and Regulatory Information for TEMOZOLOMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm TEMOZOLOMIDE temozolomide CAPSULE;ORAL 201742-006 Feb 12, 2014 AB RX No No   Start Trial   Start Trial   Start Trial
Chemi Spa TEMOZOLOMIDE temozolomide CAPSULE;ORAL 204639-005 Nov 23, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
Chartwell TEMOZOLOMIDE temozolomide CAPSULE;ORAL 206413-002 Apr 12, 2016 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.